Recipient name	Proposed FY25 awards (subject to availability of funding)
California Department of Public Health	$955,472
Chicago Department of Public Health	687,266
Delaware Health and Social Services	390,713
Florida Department of Health	1,034,315
Georgia Department of Public Health	817,044
Houston Health Department	738,464
Illinois Department of Public Health	516,350
Indiana State Department of Health	514,626
Los Angeles County Department of Public Health	874,378
Michigan Department of Health and Human Services	688,444
Mississippi State Department of Health	489,198
New Jersey Department of Health and Senior Services	898,374
New York City Department of Health and Mental Hygiene	1,306,704
New York State Department of Health	594,625
North Carolina Department of Health and Human Services	687,023
Oregon Health Authority	794,810
Pennsylvania Department of Health	524,656
Philadelphia Department of Public Health	579,853
Puerto Rico Department of Health	431,047
San Francisco Department of Public Health	643,882
Texas Department of State Health Services	735,652
Virginia Department of Health	664,068
Washington State Department of Health	738,592

Period of Performance: June 1, 2025, through May 31, 2030.

Authority: This program is authorized under Section 318 of the Public Health Service Act (42 U.S.C. 247c, as amended).

Dated: August 21, 2024.

Terrance Perry,

Acting Director, Office of Grants Services, Centers for Disease Control and Prevention.

[FR Doc. 2024–19298 Filed 8–27–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Title IV–E Programs Quarterly Financial Report (0970–0510)

AGENCY: Children's Bureau, Administration on Children, Youth and Families, Administration for Children and Families, Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Administration for Children and Families (ACF) Children's Bureau plans to submit revisions to an approved generic information collection (GenIC) under the umbrella generic: Generic Clearance for Financial Reports used for ACF Non-Discretionary Grant Programs (0970–0510). This request revises form CB–496, the Title IV–E Programs Quarterly Financial Report, used by title IV–E agencies to submit financial claims for the title IV–E entitlement grant programs.

DATES: *Comments due within 14 days of publication.* In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above and below.

ADDRESSES: Copies of the proposed collection of information can be obtained and comments may be forwarded by emailing *infocollection@acf.hhs.gov.* All requests should be identified by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: ACF programs require detailed financial information from their grantees that allows ACF to monitor various specialized cost categories within each program, to closely manage program activities, and to have sufficient financial information to enable periodic thorough and detailed audits. Generic Clearance for Financial Reports used for ACF Non-Discretionary Grant Programs allows ACF programs to efficiently develop and receive approval for financial reports that are tailored to specific funding recipients and the associated needs of the program. For more information about the umbrella generic, see: *https://www.reginfo.gov/public/do/PRAViewDocument?ref_nbr=202108-0970-002*

This specific GenIC collects quarterly cost and caseload data for five title IV–E programs (*i.e.,* foster care, adoption assistance, guardianship assistance, prevention services, and kinship navigator). The requested changes include removing reporting items no longer needed, and the addition or revision of reporting lines and instructions required due to recent changes in program regulations, policy guidance, and other operational changes for which further information will enhance the administration of the program.

Respondents: Title IV–E agencies

ANNUAL BURDEN ESTIMATES

Title of information collection	Number of respondents	Annual frequency of responses	Hourly burden per response	Annual hourly burden
Form CB–496	67	4	23	6154

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 14 days of this publication.

Authority: 42 U.S.C. 671(a)(6), 42 U.S.C. 671(a)(7), 42 U.S.C. 673(a)(8)(B) and 42 U.S.C. 674(a) and (b)

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2024–19253 Filed 8–27–24; 8:45 am]

BILLING CODE 4184–73–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–N–0008]

Patient Engagement Advisory Committee; Notice of Meeting—Patient-Centered Informed Consent in Clinical Study

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Patient Engagement Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.

DATES: The meeting will be held on October 30, 2024, from 10 a.m. to 5 p.m. Eastern Time.

ADDRESSES: All meeting participants will be heard, viewed, captioned, and recorded for this advisory committee meeting via an online teleconferencing and/or video conferencing platform.

Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: *https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.*

FOR FURTHER INFORMATION CONTACT: Letise Williams, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5407, Silver Spring, MD 20993–0002, *Letise.Williams@fda.hhs.gov,* 301–796–8398, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the **Federal Register** about last-minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's website at *https://www.fda.gov/AdvisoryCommittees/default.htm* and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before the meeting.

SUPPLEMENTARY INFORMATION:

Agenda: The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On October 30, 2024, the Committee will discuss and make recommendations on ''Patient-Centered Informed Consent in Clinical Study of FDA-Regulated Medical Products.'' The individuals who volunteer to participate in clinical research play an integral role in advancing scientific knowledge and supporting the development of potentially life-saving therapies for patients in need. Informed consent is a key element in clinical studies and can be one of a patient's first interactions with the clinical community. Too often, however, informed consent forms are lengthy and difficult for potential research participants to understand. FDA has worked to improve informed consent over the years, including several recent activities such as developing a draft guidance in identifying key information in informed consent.

The Committee will provide recommendations on the informed consent process and the areas of focus of the informed consent. The Committee will also provide recommendations on factors to consider when communicating informed consent to clinical study participants to increase the likelihood of participants understanding the key elements of research.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA's website at the time of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting. Background material and the link to the online teleconference and/or video conference meeting will be available at *https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm.* Scroll down and select the appropriate advisory committee meeting link. The meeting will include slide presentations with audio and video components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. Written submissions may be made to the contact person (see **FOR FURTHER INFORMATION CONTACT**) on or before October 3, 2024. Oral presentations from the public will be scheduled between approximately 2 p.m. and 3 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person (see **FOR FURTHER INFORMATION CONTACT**) and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 25, 2024. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. If the number of registrants requesting to speak during the open public hearing is greater than can be reasonably accommodated during the scheduled open hearing portion of the advisory committee meeting, FDA may conduct a lottery to determine the speakers who will be invited to participate. The contact person will notify interested persons regarding their request to speak by September 26, 2024.

Virtual Breakout Session: Individuals interested in participating in the virtual breakout scenario discussions will need to sign up to participate on or before October 16, 2024. The signup sheet, as well as additional information pertaining to the virtual scenario discussions, will be available at *https://www.fdalive.com/peac.* Everyone who signs up in advance and provides a valid email address will receive an